Firefly Neuroscience reports successful quarter with Nasdaq listing and partnerships for brain health tech.

From GlobeNewswire: 2024-11-14 17:30:00

Firefly Neuroscience, Inc. successfully listed on Nasdaq under the symbol “AIFF” and is partnering with neuroscience pharmaceutical companies to advance its dual go-to-market strategy. The company aims to improve brain health outcomes for patients with neurological and mental disorders by utilizing its FDA-cleared Brain Network Analytics (BNA™) technology.

The company is dedicated to revolutionizing diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Firefly has built a comprehensive database of brain wave tests over 15 years and is now launching BNA™ commercially to target pharmaceutical companies and medical practitioners for clinical use.

Operational and financial highlights for the third quarter of 2024 include collaborations with Bright Minds Bioscience and Zeto, Inc., as well as successful research collaborations with Takeda Pharmaceutical Company Limited and Novartis. The company completed a merger with WaveDancer Inc. and has 8,503,365 shares of common stock outstanding as of November 12, 2024.

Firefly’s CEO, Jon Olsen, expressed the company’s commitment to commercializing its BNA™ technology through strategic partnerships with pharmaceutical companies like Bright Minds, Novartis, and Takeda. These collaborations aim to drive innovations in drug development and deliver solutions to neurologists while improving outcomes for patients with brain health illnesses.



Read more at GlobeNewswire:: Firefly Neuroscience Reports Third Quarter 2024 Results and